Roche Aktie

343,55EUR
-1,75EUR
-0,51%
26.11.2021
358,60CHF
-3,45CHF
-0,95%
26.11.2021

WKN: 855167 / ISIN: CH0012032048

  Kaufen  
Verkaufen
oder
Werbung

Roche Aktien News

26.11.21
Roche Extraordinary General Meeting 2021 (Roche Holding AG)
26.11.21Roche Extraordinary General Meeting 2021 (GlobeNewswire)
23.11.21
Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders (Roche Holding AG)
23.11.21Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders (GlobeNewswire)
19.11.21
European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (Roche Holding AG)
19.11.21European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (GlobeNewswire)
18.11.21
Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care (Roche Holding AG)
18.11.21Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care (GlobeNewswire)
15.11.21
Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running (Roche Holding AG)
15.11.21Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running (GlobeNewswire)
12.11.21
Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (Roche Holding AG)
12.11.21Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
11.11.21
CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (Roche Holding AG)
11.11.21CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
04.11.21
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche (Roche Holding AG)
04.11.21[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche (GlobeNewswire)
29.10.21
IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (Roche Holding AG)
29.10.21IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (GlobeNewswire)
28.10.21Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes (PR Newswire)
28.10.21Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes (PR Newswire)
25.10.21
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research (Roche Holding AG)
25.10.21Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research (GlobeNewswire)
22.10.21
FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD) (Roche Holding AG)
22.10.21FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD) (GlobeNewswire)
22.10.21
Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab) (Roche Holding AG)
22.10.21Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab) (GlobeNewswire)
20.10.21
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months - outlook for 2021 raised (Roche Holding AG)
18.10.21Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for improved patient care (PR Newswire)
18.10.21Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for improved patient care (PR Newswire)
15.10.21
US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer (Roche Holding AG)
15.10.21US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer (GlobeNewswire)
15.10.21
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care (Roche Holding AG)
15.10.21Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care (GlobeNewswire)
14.10.21New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder (GlobeNewswire)
14.10.21
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder (Roche Holding AG)
14.10.21Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma (GlobeNewswire)
14.10.21
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma (Roche Holding AG)
13.10.21Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression i (GlobeNewswire)
08.10.21
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease (Roche Holding AG)
08.10.21[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease (GlobeNewswire)
Seite: 123456789...13

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln